SCHEMBL2873159

SCHEMBL2873159

CCOC(=O)C(=O)c1c(-c2ccc(Cl)c(S(=O)(=O)NC3CCCCC3)c2)[nH]c2cccc(Cl)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 6/20 0.44
POLB P06746 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 2/20 0.41
PI4KB Q9UBF8 1/20 0.41
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 5/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CCR8 P51685 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
BRD2 P25440 1/20 0.37
BRD3 Q15059 1/20 0.37
TP53 P04637 1/20 0.37
CASP1 P29466 1/20 0.37
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2875790 0.92 BRD4 (0.46) BRD4POLBMEN1KMT2API4KB
SCHEMBL27772052 0.87 BRD4 (0.48) BRD4MEN1KMT2API4KBALDH1A1
SCHEMBL2878010 0.87 BRD4 (0.45) BRD4POLBMEN1KMT2API4KB
SCHEMBL2875348 0.86 BRD4 (0.43) BRD4POLBMEN1KMT2ATSHR
SCHEMBL2878374 0.84 BRD4 (0.44) BRD4MEN1KMT2API4KBALDH1A1
SCHEMBL3998583 0.84 BRD4 (0.46) BRD4POLBMEN1KMT2API4KB
SCHEMBL27751386 0.83 BRD4 (0.46) BRD4MEN1KMT2API4KBALDH1A1
SCHEMBL27772050 0.83 BRD4 (0.44) BRD4POLBMEN1KMT2ATSHR
SCHEMBL2880668 0.82 BRD4 (0.45) BRD4POLBMEN1KMT2API4KB
SCHEMBL27751371 0.81 BRD4 (0.43) BRD4POLBMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066628-B1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI AVENTIS (FR) 2010-10-20 EP disclosed
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
EP-2066628-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2009-06-10 EP disclosed
WO-2008014186-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176804-A1 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS PTGER2, PTGDR2, CYSLTR2 BRD4 1328/4885POLB 3699/4885MEN1 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.